ArticlePharmaceuticals (Basel, Switzerland)2023
The Adapted POM Analysis of Avenanthramides In Silico.
Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Avenanthramides as digestion-stage modulators: Mechanistic links across the gastrointestinal continuum.Food chemistry: X · 2026Review
- Myricetin ameliorates letrozole-induced PCOS in female rats-a mechanistic approach through in silico, in vitro, and in vivo study via P13/AKT and NF-κB pathway crosstalk.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Applications of Opuntia ficus-indica (L.) mill seed oil from eastern morocco including chemical profiling, antibacterial activity, and docking.Scientific reports · 2026Article
- Phytochemical and Computational Discovery of Potent Xanthine Oxidase Inhibitors From Ziziphus lotus L. Leaves and Seeds.Chemistry & biodiversity · 2026Article
- Improving quercetin solubility via structural modification enhances dual-target coronavirus entry: an integrated in-vitro and in-silico study.Scientific reports · 2025Article
- Synthesis and radiolabelled evaluation of novel pyrimidine derivatives as dual α-amylase inhibitors and GIT-targeted molecular imaging probe.RSC advances · 2025Article
- Bio-computational modeling, POM analysis and molecular dynamic simulation for novel synthetic quinolone and benzo[d][1,3]oxazine candidates as antimicrobial inhibitors.Scientific reports · 2024Article
- Heterocycles 52: The Drug-Likeness Analysis of Anti-Inflammatory Thiazolo[3,2-b][1,2,4]triazole and Imidazo[2,1-b][1,3,4]thiadiazole Derivatives.Pharmaceuticals (Basel, Switzerland) · 2024Article
- CuO nanoparticles for green synthesis of significant anti-Helicobacter pylori compounds with in silico studies.Scientific reports · 2024Article
- In Vitro and In Silico Evaluation of Antiproliferative Activity of New Isoxazolidine Derivatives Targeting EGFR: Design, Synthesis, Cell Cycle Analysis, and Apoptotic Inducers.Pharmaceuticals (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
POM analysis and related approaches are significant tools based on calculating various physico-chemical properties and predicting biological activity, ADME parameters, and toxicity of a molecule. These methods are used to evaluate a molecule's potential to become a drug candidate. Avenanthramides (AVNs) are promising secondary metabolites specific to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.